DGIdb - RIZATRIPTAN Drug Record

RIZATRIPTAN CHEMBL905 FDA Approved

Alternate Names:

Rizatriptan
Maxalt
Maxalt-Mlt
MK-462
MK 462 FREE BASE
RIZATRIPTANUM
BIDD:GT0361
RIZATRIPTAN (INN)
MOLPORT-003-666-600
AC1L1JK9
1H-INDOLE-3-ETHANAMINE, N,N-DIMETHYL-5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-
N,N-DIMETHYL-2-[5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL]-ETHANAMINE
UNII-51086HBW8G
RIZATRIPTAN BENZOAT
5078
144034-80-0
CHEBI:48273
N,N-DIMETHYL-2-[5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL]ETHANAMINE
LS-83053
SPECTRUM1505189
NCGC00095899-01
TL8000966
DB00953
AC-1712
RISATRIPTAN
N,N-DIMETHYL-2-[5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL]ETHYLAMINE
7854588
L000812
C093622
N,N-DIMETHYL-5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOLE-3-ETHANAMINE
D08485
N,N-DIMETHYL-2-[5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL]ETHANAMINE
145202-66-0
RIZATRIPTAN [INN:BAN]
DAP000220
CID5078
I06-2272
Van-rizatriptan ODT
Van-rizatriptan
Teva-rizatriptan ODT
Teva-rizatriptan
Sandoz Rizatriptan ODT
Rizatriptan Rdt
Rizatriptan ODT
Rizaport
Riva-rizatriptan ODT
Q-rizatriptan ODT
PMS-rizatriptan Rdt
Nat-rizatriptan ODT
Nat-rizatriptan
Mylan-rizatriptan ODT
Mylan-rizatriptan
Mint-rizatriptan ODT
Maxalt Rpd
Maxalt MLT
Mar-rizatriptan
Jamp-rizatriptan Ir
Jamp-rizatriptan
Ipg-rizatriptan
Dom-rizatriptan Rdt
Auro-rizatriptan ODT
Auro-rizatriptan
Apo-rizatriptan Rpd
Apo-rizatriptan
Act Rizatriptan ODT
Act Rizatriptan
178101771
FAS LIGAND
FASLG
DIMETHYL-[2-(5-[1,2,4]TRIAZOL-1-YLMETHYL-1H-INDOL-3-YL)-ETHYL]-AMINE
Q-201675
3B2-6282
A808161
AB00698277-07
AB00698277-05
S-5530
CAS-144034-80-0
4CH-007687
ST2409343
KB-300182
SMR000469172
SC-17974
LP074528
DR000842
BR-72890
BC201784
AK-72890
AJ-08257
NCGC00095899-04
RL01798
AN-5270
AKOS015896596
FC0031
BDBM50033437
TOX21_111534
ZINC5895
IND062
MLS006010229
CC-317
SCHEMBL26662
DSSTOX_GSID_23565
DSSTOX_RID_77082
GTPL51
DSSTOX_CID_3565
PUBCHEM16714
RIZATRIPTAN;
MAXALTREG
MK-A462
DIMETHYL({2-[5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL]ETHYL})AMINE
ULFRLSNUDGIQQP-UHFFFAOYSA-N
2-(5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-1H-INDOL-3-YL)-N,N-DIMETHYLETHANAMINE
51086HBW8G
135650905
51
C1538
FAS-LIGAND

Drug Info:

Drug Class	anti-migraine agents
Year of Approval	1998
Drug Categories	serotonin receptor agonists
Drug Categories	serotonin modulators
Drug Categories	serotonin agents
Drug Categories	serotonin 5-ht1 receptor agonists
Drug Categories	selective serotonin (5ht1) agonists
Drug Categories	physiological effects of drugs
Drug Categories	pharmacologic actions
Drug Categories	organic chemicals
Drug Categories	neurotransmitter agents
Drug Categories	nervous system
Drug Categories	molecular mechanisms of pharmacological action
Drug Categories	migraine disorders
Drug Categories	indoles
Drug Categories	heterocyclic compounds, 2-ring
Drug Categories	heterocyclic compounds, 1-ring
Drug Categories	heterocyclic compounds
Drug Categories	cytochrome p-450 cyp1a2 substrates
Drug Categories	chemical actions and uses
Drug Categories	biogenic monoamines
Drug Categories	biogenic amines
Drug Categories	azoles
Drug Categories	antimigraine preparations
Drug Categories	analgesics
Drug Categories	amines
Drug Groups	approved
Drug Type	small molecule
Name of the Ligand Species (if a Peptide)	Human
FDA Approval	1998
Drug Class	small molecule
Drug Indications	Anti-migraine Agents

(5 More Sources)

Publications:

Ikemoto et al., 2004, [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]., Nippon Yakurigaku Zasshi
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Longmore et al., Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols., Funct. Neurol.
Longmore et al., 1996, 5-HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519., Br J Clin Pharmacol
Williamson et al., 2001, The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs., Br. J. Pharmacol.
Wackenfors et al., 2005, Triptans induce vasoconstriction of human arteries and veins from the thoracic wall., J. Cardiovasc. Pharmacol.
Sciberras et al., 1997, Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist., Br J Clin Pharmacol
Wellington et al., 2002, Spotlight on rizatriptan in migraine., CNS Drugs
Wellington et al., 2002, Rizatriptan: an update of its use in the management of migraine., Drugs
Pauwels et al., 1998, Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state., Naunyn Schmiedebergs Arch. Pharmacol.
Villalón et al., 2002, An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy., Proc. West. Pharmacol. Soc.
Goadsby et al., 2003, Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input., Neuroscience
Wainscott et al., 1998, Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation., Eur. J. Pharmacol.
Villalón et al., 2003, Migraine: pathophysiology, pharmacology, treatment and future trends., Curr Vasc Pharmacol
Villunger et al., 2000, Fas ligand, Bcl-2, granulocyte colony-stimulating factor, and p38 mitogen-activated protein kinase: Regulators of distinct cell death and survival pathways in granulocytes., J. Exp. Med.
Yu et al., 2003, Synergism of Fas-mediated apoptosis and tumor necrosis factor on adriamycin cytotoxicity to transitional cell carcinoma., Urol. Int.
Srivastava et al., 1999, Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription., J. Exp. Med.
Tagami et al., Fas-mediated apoptosis in acute alcoholic hepatitis., Hepatogastroenterology
da Rocha Dias et al., 2001, CTLA-4 blockade of antigen-induced cell death., Blood
Wakao et al., 2000, Involvement of granzyme B expression in the enhancement of natural killer activity by beta-endorphin., Brain Behav. Immun.
Kawano et al., 2002, Decreased akt activity is associated with activation of forkhead transcription factor after transient forebrain ischemia in gerbil hippocampus., J. Cereb. Blood Flow Metab.
Ishida et al., 2003, Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease., Nat. Med.
Vij et al., 2004, Lumican suppresses cell proliferation and aids Fas-Fas ligand mediated apoptosis: implications in the cornea., Exp. Eye Res.
Chaturvedi et al., 2005, Augmentation of Fas ligand-induced apoptosis by MUC1 mucin., Int. J. Oncol.
Pardo et al., 2003, Differential implication of protein kinase C isoforms in cytotoxic T lymphocyte degranulation and TCR-induced Fas ligand expression., Int. Immunol.
Cullen et al., 2004, Activation of cAMP-guanine exchange factor confers PKA-independent protection from hepatocyte apoptosis., Am. J. Physiol. Gastrointest. Liver Physiol.
Chen et al., 2002, Luteotropic roles of prolactin in early pregnant hamsters., Biol. Reprod.
Zhang et al., Apoptotic response to 5-fluorouracil treatment is mediated by reduced polyamines, non-autocrine Fas ligand and induced tumor necrosis factor receptor 2., Cancer Biol. Ther.
Song et al., 2003, Vitamin D(3) up-regulating protein 1 (VDUP1) antisense DNA regulates tumorigenicity and melanogenesis of murine melanoma cells via regulating the expression of fas ligand and reactive oxygen species., Immunol. Lett.
Siegmund et al., 2001, Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway., J. Biol. Chem.

RIZATRIPTAN HTR1A

Interaction Types:

agonist

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Publications:
RIZATRIPTAN HTR1E

Interaction Types:

agonist

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Publications:

RIZATRIPTAN HTR1D

Interaction Types:

agonist

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Direct Interaction? True

Publications:

Ikemoto et al., 2004, [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]., Nippon Yakurigaku Zasshi

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

Longmore et al., Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols., Funct. Neurol.

RIZATRIPTAN HTR1B

Interaction Types:

agonist

Interaction Info:

Trial Name -

Novel drug target Established target

Specific Action of the Ligand Partial agonist

Publications:

Ikemoto et al., 2004, [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]., Nippon Yakurigaku Zasshi

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

Pauwels et al., 1998, Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state., Naunyn Schmiedebergs Arch. Pharmacol.

RIZATRIPTAN HTR1F

Interaction Types:

agonist

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Publications:

Villalón et al., 2002, An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy., Proc. West. Pharmacol. Soc.

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

Goadsby et al., 2003, Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input., Neuroscience

RIZATRIPTAN FAS

Interaction Types:

n/a

Interaction Info:

Specific Action of the Ligand None

Endogenous Drug? True

Publications:

Villunger et al., 2000, Fas ligand, Bcl-2, granulocyte colony-stimulating factor, and p38 mitogen-activated protein kinase: Regulators of distinct cell death and survival pathways in granulocytes., J. Exp. Med.

Yu et al., 2003, Synergism of Fas-mediated apoptosis and tumor necrosis factor on adriamycin cytotoxicity to transitional cell carcinoma., Urol. Int.

RIZATRIPTAN BCL2

Interaction Types:

n/a

Interaction Info:

Publications:

Srivastava et al., 1999, Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription., J. Exp. Med.
RIZATRIPTAN CASP3

Interaction Types:

n/a

Interaction Info:

Publications:

Tagami et al., Fas-mediated apoptosis in acute alcoholic hepatitis., Hepatogastroenterology
RIZATRIPTAN CTLA4

Interaction Types:

n/a

Interaction Info:

Publications:

da Rocha Dias et al., 2001, CTLA-4 blockade of antigen-induced cell death., Blood
RIZATRIPTAN FCGR3A

Interaction Types:

n/a

Interaction Info:

Publications:

Wakao et al., 2000, Involvement of granzyme B expression in the enhancement of natural killer activity by beta-endorphin., Brain Behav. Immun.
RIZATRIPTAN FCGR3B

Interaction Types:

n/a

Interaction Info:

Publications:

Wakao et al., 2000, Involvement of granzyme B expression in the enhancement of natural killer activity by beta-endorphin., Brain Behav. Immun.

RIZATRIPTAN FOXO1

Interaction Types:

n/a

Interaction Info:

Publications:

Kawano et al., 2002, Decreased akt activity is associated with activation of forkhead transcription factor after transient forebrain ischemia in gerbil hippocampus., J. Cereb. Blood Flow Metab.

RIZATRIPTAN ITGB2

Interaction Types:

n/a

Interaction Info:

Publications:

Ishida et al., 2003, Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease., Nat. Med.
RIZATRIPTAN LUM

Interaction Types:

n/a

Interaction Info:

Publications:

Vij et al., 2004, Lumican suppresses cell proliferation and aids Fas-Fas ligand mediated apoptosis: implications in the cornea., Exp. Eye Res.
RIZATRIPTAN MUC1

Interaction Types:

n/a

Interaction Info:

Publications:

Chaturvedi et al., 2005, Augmentation of Fas ligand-induced apoptosis by MUC1 mucin., Int. J. Oncol.

RIZATRIPTAN PIK3CG

Interaction Types:

n/a

Interaction Info:

Publications:

Pardo et al., 2003, Differential implication of protein kinase C isoforms in cytotoxic T lymphocyte degranulation and TCR-induced Fas ligand expression., Int. Immunol.

Cullen et al., 2004, Activation of cAMP-guanine exchange factor confers PKA-independent protection from hepatocyte apoptosis., Am. J. Physiol. Gastrointest. Liver Physiol.

RIZATRIPTAN PRL

Interaction Types:

n/a

Interaction Info:

Publications:

Chen et al., 2002, Luteotropic roles of prolactin in early pregnant hamsters., Biol. Reprod.
RIZATRIPTAN TP53

Interaction Types:

n/a

Interaction Info:

Publications:

Zhang et al., Apoptotic response to 5-fluorouracil treatment is mediated by reduced polyamines, non-autocrine Fas ligand and induced tumor necrosis factor receptor 2., Cancer Biol. Ther.

RIZATRIPTAN TXNIP

Interaction Types:

n/a

Interaction Info:

Publications:

Song et al., 2003, Vitamin D(3) up-regulating protein 1 (VDUP1) antisense DNA regulates tumorigenicity and melanogenesis of murine melanoma cells via regulating the expression of fas ligand and reactive oxygen species., Immunol. Lett.

RIZATRIPTAN FADD

Interaction Types:

n/a

Interaction Info:

Publications:

Siegmund et al., 2001, Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway., J. Biol. Chem.

DrugBank: DB00953

Version: 5.0.8

Alternate Names:

RIZATRIPTAN DrugBank Drug Name

N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine Drug Synonym

N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine Drug Synonym

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories amines

Publications:

Villalón et al., 2002, An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy., Proc. West. Pharmacol. Soc.

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

Goadsby et al., 2003, Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input., Neuroscience

TEND: RIZATRIPTAN
- Version: 01-August-2011
Alternate Names:

RIZATRIPTAN Primary Drug Name

Drug Info:

Year of Approval 1998

Drug Class anti-migraine agents

Publications:
GuideToPharmacologyInteractions: 5078
- Version: 27-September-2017
Alternate Names:

FASLG Gene Symbol (for Endogenous Peptides)

FAS LIGAND GuideToPharmacology Ligand Name

178101771 PubChem Drug SID

Drug Info:

Name of the Ligand Species (if a Peptide) Human

Publications:
TdgClinicalTrial: RIZATRIPTAN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Anti-migraine Agents

Drug Class small molecule

FDA Approval 1998

Publications:

NCI: FAS LIGAND

Version: 14-September-2017

Alternate Names:

C1538 NCI drug code

Drug Info:

Publications:

Srivastava et al., 1999, Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription., J. Exp. Med.

Wakao et al., 2000, Involvement of granzyme B expression in the enhancement of natural killer activity by beta-endorphin., Brain Behav. Immun.

Pardo et al., 2003, Differential implication of protein kinase C isoforms in cytotoxic T lymphocyte degranulation and TCR-induced Fas ligand expression., Int. Immunol.

NCI: FAS-LIGAND

Version: 14-September-2017

Alternate Names:

C1538 NCI drug code

Drug Info:

Publications:

Ishida et al., 2003, Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease., Nat. Med.

da Rocha Dias et al., 2001, CTLA-4 blockade of antigen-induced cell death., Blood

Chen et al., 2002, Luteotropic roles of prolactin in early pregnant hamsters., Biol. Reprod.

TTD: DAP000220
- Version: 4.3.02 (25-August-2011)
Alternate Names:

I06-2272 Drug Synonym

CID5078 Drug Synonym

DAP000220 TTD Drug Id

Drug Info:

Publications:
PubChem: RIZATRIPTAN
- Version: 09-Feb-2016
Alternate Names:

51086HBW8G Drug Synonym

RIZATRIPTAN pubchem_primary_name

5078 PubChem CID

Drug Info:

Publications:
GuideToPharmacologyInteractions: 51
- Version: 27-September-2017
Alternate Names:

RIZATRIPTAN GuideToPharmacology Ligand Name

135650905 PubChem Drug SID

Drug Info:

Publications:

Specific Action of the Ligand	Full agonist
Endogenous Drug?	False

Trial Name	-
Novel drug target	Established target
Specific Action of the Ligand	Partial agonist

RIZATRIPTAN	DrugBank Drug Name
N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine	Drug Synonym
N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine	Drug Synonym

FASLG	Gene Symbol (for Endogenous Peptides)
FAS LIGAND	GuideToPharmacology Ligand Name
178101771	PubChem Drug SID

RIZATRIPTAN Drug Record

RIZATRIPTAN CHEMBL905 FDA Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types: agonist

Interaction Info: Specific Action of the Ligand Full agonist Endogenous Drug? False

Publications:

Interaction Types: agonist

Interaction Info: Specific Action of the Ligand Full agonist Endogenous Drug? False

Publications:

Interaction Types: agonist

Interaction Info: Specific Action of the Ligand Full agonist Endogenous Drug? False Direct Interaction? True

Interaction Types: agonist

Interaction Info: Trial Name - Novel drug target Established target Specific Action of the Ligand Partial agonist

Interaction Types: agonist

Interaction Info: Specific Action of the Ligand Full agonist Endogenous Drug? False

Interaction Types: n/a

Interaction Info: Specific Action of the Ligand None Endogenous Drug? True

Interaction Types: n/a

Interaction Info:

Publications: Srivastava et al., 1999, Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription., J. Exp. Med.

Interaction Types: n/a

Interaction Info:

Publications: Tagami et al., Fas-mediated apoptosis in acute alcoholic hepatitis., Hepatogastroenterology

Interaction Types: n/a

Interaction Info:

Publications: da Rocha Dias et al., 2001, CTLA-4 blockade of antigen-induced cell death., Blood

Interaction Types: n/a

Interaction Info:

Publications: Wakao et al., 2000, Involvement of granzyme B expression in the enhancement of natural killer activity by beta-endorphin., Brain Behav. Immun.

Interaction Types: n/a

Interaction Info:

Publications: Wakao et al., 2000, Involvement of granzyme B expression in the enhancement of natural killer activity by beta-endorphin., Brain Behav. Immun.

Interaction Types: n/a

Interaction Info:

Publications: Kawano et al., 2002, Decreased akt activity is associated with activation of forkhead transcription factor after transient forebrain ischemia in gerbil hippocampus., J. Cereb. Blood Flow Metab.

Interaction Types: n/a

Interaction Info:

Publications: Ishida et al., 2003, Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease., Nat. Med.

Interaction Types: n/a

Interaction Info:

Publications: Vij et al., 2004, Lumican suppresses cell proliferation and aids Fas-Fas ligand mediated apoptosis: implications in the cornea., Exp. Eye Res.

Interaction Types: n/a

Interaction Info:

Publications: Chaturvedi et al., 2005, Augmentation of Fas ligand-induced apoptosis by MUC1 mucin., Int. J. Oncol.

Interaction Types: n/a

Interaction Info:

Interaction Types: n/a

Interaction Info:

Publications: Chen et al., 2002, Luteotropic roles of prolactin in early pregnant hamsters., Biol. Reprod.

Interaction Types: n/a

Interaction Info:

Publications: Zhang et al., Apoptotic response to 5-fluorouracil treatment is mediated by reduced polyamines, non-autocrine Fas ligand and induced tumor necrosis factor receptor 2., Cancer Biol. Ther.

Interaction Types: n/a

Interaction Info:

Publications: Song et al., 2003, Vitamin D(3) up-regulating protein 1 (VDUP1) antisense DNA regulates tumorigenicity and melanogenesis of murine melanoma cells via regulating the expression of fas ligand and reactive oxygen species., Immunol. Lett.

Interaction Types: n/a

Interaction Info:

Publications: Siegmund et al., 2001, Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway., J. Biol. Chem.

DrugBank: DB00953

Alternate Names: RIZATRIPTAN DrugBank Drug Name N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine Drug Synonym N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine Drug Synonym

Drug Info: Drug Type small molecule Drug Groups approved Drug Categories amines

TEND: RIZATRIPTAN

Alternate Names: RIZATRIPTAN Primary Drug Name

Drug Info: Year of Approval 1998 Drug Class anti-migraine agents

Publications:

GuideToPharmacologyInteractions: 5078

Alternate Names: FASLG Gene Symbol (for Endogenous Peptides) FAS LIGAND GuideToPharmacology Ligand Name 178101771 PubChem Drug SID

Drug Info: Name of the Ligand Species (if a Peptide) Human

Publications:

TdgClinicalTrial: RIZATRIPTAN

Alternate Names:

Drug Info: Drug Indications Anti-migraine Agents Drug Class small molecule FDA Approval 1998

Publications:

NCI: FAS LIGAND

Alternate Names: C1538 NCI drug code

Drug Info:

NCI: FAS-LIGAND

Alternate Names: C1538 NCI drug code

Interaction Types:

agonist

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Interaction Types:

agonist

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Interaction Types:

agonist

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Direct Interaction? True

Interaction Types:

agonist

Interaction Info:

Trial Name -

Novel drug target Established target

Specific Action of the Ligand Partial agonist

Interaction Types:

agonist

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Interaction Types:

n/a

Interaction Info:

Specific Action of the Ligand None

Endogenous Drug? True

Interaction Types:

n/a

Publications:

Srivastava et al., 1999, Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription., J. Exp. Med.

Interaction Types:

n/a

Publications:

Tagami et al., Fas-mediated apoptosis in acute alcoholic hepatitis., Hepatogastroenterology

Interaction Types:

n/a

Publications:

da Rocha Dias et al., 2001, CTLA-4 blockade of antigen-induced cell death., Blood

Interaction Types:

n/a

Publications:

Wakao et al., 2000, Involvement of granzyme B expression in the enhancement of natural killer activity by beta-endorphin., Brain Behav. Immun.

Interaction Types:

n/a

Publications:

Wakao et al., 2000, Involvement of granzyme B expression in the enhancement of natural killer activity by beta-endorphin., Brain Behav. Immun.

Interaction Types:

n/a

Publications:

Kawano et al., 2002, Decreased akt activity is associated with activation of forkhead transcription factor after transient forebrain ischemia in gerbil hippocampus., J. Cereb. Blood Flow Metab.

Interaction Types:

n/a

Publications:

Ishida et al., 2003, Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease., Nat. Med.

Interaction Types:

n/a

Publications:

Vij et al., 2004, Lumican suppresses cell proliferation and aids Fas-Fas ligand mediated apoptosis: implications in the cornea., Exp. Eye Res.

Interaction Types:

n/a

Publications:

Chaturvedi et al., 2005, Augmentation of Fas ligand-induced apoptosis by MUC1 mucin., Int. J. Oncol.

Interaction Types:

n/a

Interaction Types:

n/a

Publications:

Chen et al., 2002, Luteotropic roles of prolactin in early pregnant hamsters., Biol. Reprod.

Interaction Types:

n/a

Publications:

Zhang et al., Apoptotic response to 5-fluorouracil treatment is mediated by reduced polyamines, non-autocrine Fas ligand and induced tumor necrosis factor receptor 2., Cancer Biol. Ther.

Interaction Types:

n/a

Publications:

Song et al., 2003, Vitamin D(3) up-regulating protein 1 (VDUP1) antisense DNA regulates tumorigenicity and melanogenesis of murine melanoma cells via regulating the expression of fas ligand and reactive oxygen species., Immunol. Lett.

Interaction Types:

n/a

Publications:

Siegmund et al., 2001, Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway., J. Biol. Chem.

Alternate Names:

RIZATRIPTAN DrugBank Drug Name

N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine Drug Synonym

N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine Drug Synonym

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories amines

Alternate Names:

RIZATRIPTAN Primary Drug Name

Drug Info:

Year of Approval 1998

Drug Class anti-migraine agents

Alternate Names:

FASLG Gene Symbol (for Endogenous Peptides)

FAS LIGAND GuideToPharmacology Ligand Name

178101771 PubChem Drug SID

Drug Info:

Name of the Ligand Species (if a Peptide) Human

Drug Info:

Drug Indications Anti-migraine Agents

Drug Class small molecule

FDA Approval 1998

Alternate Names:

C1538 NCI drug code

Alternate Names:

C1538 NCI drug code

Alternate Names:

I06-2272 Drug Synonym

CID5078 Drug Synonym

DAP000220 TTD Drug Id

Alternate Names:

51086HBW8G Drug Synonym

RIZATRIPTAN pubchem_primary_name

5078 PubChem CID

Alternate Names:

RIZATRIPTAN GuideToPharmacology Ligand Name

135650905 PubChem Drug SID